Oragenics INC 8-K filings

Oragenics, Inc. successfully closed a public offering, raising approximately $4.45 million to support the development of its ONP-002 product candidate and for general corporate purposes.

Oragenics, Inc. has completed the manufacturing of its spray-dried drug and intranasal device filling for its lead candidate, ONP-002, in preparation for a Phase IIa clinical trial for concussed patients.

Oragenics, Inc. received a delisting notice from NYSE American for non-compliance with listing standards, while also announcing advancements in its concussion drug, ONP-002.

Oragenics' lead concussion drug candidate, ONP-002, has demonstrated stability across a wide temperature range, eliminating the need for cold storage.

Oragenics announced that its lead drug candidate, ONP-002, for treating concussions, has successfully completed a study showing no evidence of DNA damage, clearing a path for a planned Phase II clinical trial.

Oragenics announced that its lead drug candidate, ONP-002, for treating concussions, has successfully completed cardiotoxicity testing, indicating a strong safety profile.

Oragenics, Inc. has postponed its 2023 Annual Meeting of Shareholders, originally scheduled for August 26, 2024, with a new date to be announced later.

Oragenics has developed an enhanced intranasal formulation of its lead drug candidate, ONP-002, designed to improve brain uptake for the treatment of concussions.

Oragenics, Inc. has successfully closed a public offering, raising approximately $1.1 million to support the development of its ONP-002 product candidate and for general corporate purposes.

Oragenics has received approval from NYSE American for its plan to regain compliance with listing standards, with a deadline set for October 18, 2025.

Oragenics Inc. has rescheduled its 2023 Annual Meeting of Shareholders to August 26, 2024, and set a new deadline of June 21, 2024, for shareholder proposals.

Oragenics has appointed Dr. William Frank Peacock as Chief Clinical Officer to oversee the upcoming Phase II clinical trial for their concussion treatment, ONP-002.

Oragenics, Inc. will host a webinar panel on Neurotrauma Medicine to discuss Traumatic Brain Injury and present its lead drug candidate, ONP-002.

Oragenics, Inc. announces progress in its drug development program for ONP-002, a neurosteroid treatment for mild Traumatic Brain Injury (mTBI), with preparations underway for a Phase II clinical trial.

Oragenics, Inc. has announced a partnership with Avance Clinical to conduct a Phase II clinical trial in Australia for its drug candidate ONP-002, aimed at treating mild traumatic brain injury (concussion).

Oragenics, Inc. has received a notice from the NYSE American for non-compliance with continued listing standards due to insufficient stockholders' equity.

Oragenics Inc. has moved its 2023 Annual Meeting of Shareholders to July 15, 2024, and set a new deadline of May 20, 2024, for shareholder proposals.

Oragenics has appointed Dr. James Kelly as Chief Medical Officer to oversee the upcoming Phase II clinical trial for their concussion treatment drug, ONP-002.

Oragenics, Inc. has successfully closed a public offering, raising $2.1 million to support the development of its neurological drug candidate, ONP-002, and for general corporate purposes.

Oragenics has priced a public offering of 1.4 million shares at $1.50 per share, raising $2.1 million to advance its neurological drug pipeline.

Oragenics, Inc. has announced a proposed public offering of its common stock to fund the development of its neurosteroid drug compound and for general corporate purposes.

Oragenics, Inc. has announced the departure of CEO Kimberly Murphy, effective February 12, 2024, with Chairman Charlie Pope stepping in as interim Executive Chairman and President Michael Redmond appointed as Interim Principal Executive Officer.

Oragenics, Inc. has announced the expiration of its investment banking engagement agreement and will not extend it due to current market conditions.

Oragenics, Inc. is advancing its novel drug-device combination, ONP-002, into Phase II clinical trials for the treatment of mild traumatic brain injury, commonly known as concussion.

Oragenics, Inc. has terminated its at-the-market equity offering program, effective January 30, 2024.

Oragenics has acquired neurology assets from Odyssey Health, including a promising concussion treatment, and will prioritize its development while pausing other programs.